Ajabnoor Rana, Althubaiti Reem, Hafiz Bayan, Khashoggi Khalid, Almutairi Heba, Reda Bashar
Department of Pathology, Faculty of Medicine, King Abdulaziz University and King Abdulaziz University Hospital, Jeddah 22252, Saudi Arabia.
Hafr Al-Batin Health Cluster Regional Laboratory, Ministry of Health, Hafr Al-Batin, Saudi Arabia.
Int J Surg Case Rep. 2024 Dec;125:110570. doi: 10.1016/j.ijscr.2024.110570. Epub 2024 Nov 8.
INTRODUCTION & IMPORTANCE: Parosteal osteosarcoma is an uncommon, low-grade, well differentiated malignant bone neoplasm with a more favorable prognosis compared to other types of osteosarcoma. Dedifferentiation is a well-known phenomenon, observed in 16-24.6 % of cases, leads to a combination of low-grade fibroblastic osteosarcoma and high-grade sarcoma. The dedifferentiated component is typically high-grade conventional osteosarcoma, although unusual variants such as spindle cell sarcoma, telangiectatic osteosarcoma, and rhabdomyosarcomatous dedifferentiation may arise. This case report contributes significant information to the sparse literature on dedifferentiated parosteal osteosarcoma due to its distinctive characteristics.
We describe a rare presentation of dedifferentiated parosteal osteosarcoma in a 44-year-old male with a lesion in the left femur. The dedifferentiated component included low-grade leiomyosarcoma alongside high-grade conventional osteosarcoma, presenting a diagnostic challenge, particularly with limited biopsy material. Diagnosis was confirmed using fluorescence in situ hybridization (FISH) for MDM2 gene amplification, emphasizing the importance of molecular diagnostic testing in such complex cases.
This case highlights a rare presentation of dedifferentiated parosteal osteosarcoma (DPO) with low-grade leiomyosarcomatous and high-grade osteosarcomatous components, posing significant diagnostic challenges. Accurate diagnosis required a multidisciplinary approach, including imaging, histopathology, and MDM2 gene amplification testing, especially given the limitations of initial biopsy samples. Early recognition of dedifferentiation is critical due to its impact on metastasis risk and treatment planning. The case underscores the need for personalized treatment strategies and vigilant long-term follow-up in managing rare bone tumors like DPO.
This case presenting a distinctive pattern of dedifferentiation is, to our knowledge, the first documented case of low-grade leiomyosarcoma occurring in parosteal osteosarcoma. As it enhances the clinical understanding by broadening the range of dedifferentiated components identified in parosteal osteosarcoma and highlights the diagnostic difficulties associated with these uncommon bone tumors.
骨旁骨肉瘤是一种罕见的、低级别、高分化的恶性骨肿瘤,与其他类型的骨肉瘤相比,预后更为良好。去分化是一种众所周知的现象,在16% - 24.6%的病例中可见,会导致低级别纤维母细胞性骨肉瘤和高级别肉瘤的组合。去分化成分通常为高级别传统骨肉瘤,不过也可能出现诸如梭形细胞肉瘤、毛细血管扩张性骨肉瘤和横纹肌肉瘤样去分化等不常见的变异类型。本病例报告因其独特特征,为关于去分化骨旁骨肉瘤的稀少文献提供了重要信息。
我们描述了一名44岁男性左股骨出现病变的罕见去分化骨旁骨肉瘤病例。去分化成分包括低级别平滑肌肉瘤以及高级别传统骨肉瘤,这带来了诊断挑战,尤其是在活检材料有限的情况下。通过对MDM2基因扩增进行荧光原位杂交(FISH)确诊,强调了分子诊断检测在这类复杂病例中的重要性。
本病例突出了具有低级别平滑肌肉瘤和高级别骨肉瘤成分的去分化骨旁骨肉瘤(DPO)的罕见表现,带来了重大诊断挑战。准确诊断需要多学科方法,包括影像学、组织病理学和MDM2基因扩增检测,特别是考虑到初始活检样本的局限性。由于去分化对转移风险和治疗规划有影响,早期识别去分化至关重要。该病例强调了在管理像DPO这样的罕见骨肿瘤时,需要个性化治疗策略和密切的长期随访。
据我们所知,本病例呈现出独特的去分化模式,是骨旁骨肉瘤中出现低级别平滑肌肉瘤的首例记录病例。因为它通过拓宽骨旁骨肉瘤中识别出的去分化成分范围,增强了临床认识,并突出了与这些不常见骨肿瘤相关的诊断困难。